<p>Loss of Cirbp expression is correlated with the malignant progression and poor prognosis in nasopharyngeal carcinoma</p>

Abstract

Purpose: The correlation of cold-inducible RNA-binding protein (Cirbp) expression with clinicopathological features including patient prognosis in nasopharyngeal carcinoma (NPC) was investigated. Methods: The expression of Cirbp in NPC cell lines and tissue specimens was examined by qRT-PCR or immunohistochemistry (IHC). Results: Immunohistochemistry (IHC) results showed that high Cirbp expression was detected in 61 of 61 non-cancerous nasopharyngeal squamous epithelial biopsies, whereas the significantly reduced expression of Cirbp was observed in NPC specimens. In addition, IHC assay for Cirbp protein illustrated that the cells of 177 NPC samples and nasopharyngeal squamous epithlial cells displayed strong signals in nuclei and faint signals in cytoplasm, whereas Cirbp protein is mainly detected in the cell’s cytoplasm in many other cancers. More importantly, TNM classification displayed that the low expression of Cirbp was more frequently observed in T3-T4, N2-N3, M1 and III-IV NPC biopsies, and undifferentiated carcinoma (UDC) than T1-T2, N0-N1, M0 and I-II tumors, and differentiated nonkeratinizing carcinoma (DNKC), suggesting that Cirbp loss is a key molecular event in advanced cases of NPC. Kaplan–Meier survival analysis indicated that NPC patients showing lower Cirbp expression had a significantly shorter overall survival time than those with high Cirbp expression. Multivariate analysis suggested that the level of Cirbp expression was an independent prognostic indicator for NPC survival. Finally, we revealed a significant positive association between Cirbp expression and E-cadherin, and a notable negative correlation between Cirbp expression and Ki67 labeling index in NPC biopsies. Conclusion: Collectively, these findings demonstrate that loss of Cirbp expression is correlated with malignant progression and poor prognosis in NPC.

Translate the untranslated: excising as a novel post-splicing event

“…The role of CIRBP in tumorigenesis remains controversial. In some cases, it has an oncogenic function (16), while in other studies, it acts as a tumor suppressor (17). According to our results, besides canonical alternative splicing, CIRBP has a splicing-independent low accuracy mechanism of mRNA diversity generation.…”

Investigating the Role of Telomere and Telomerase Associated Genes and Proteins in Endometrial Cancer

“…CIRBP , which has previously been found at the telomeres of a telomerase-positive cell line [ 110 ], was downregulated in stage IV disease and associated with a favourable prognosis. Previous studies have also linked loss of CIRBP expression with malignant progression of nasopharyngeal carcinoma [ 232 ]. RPS6KA1 , WFS1 , ANAPC4 and TUBB4A have not been investigated in EC prior to this, and further studies are indicated to elucidate how these genes may affect survival in cancer in general, as well as their role in EC.…”

The Construction of Bone Metastasis-Specific Prognostic Model and Co-expressed Network of Alternative Splicing in Breast Cancer

“…CIRBP, cold-inducible RNA-binding protein, belonging to the cold-shock protein family, is expressed in different cell types and was involved in various cancer pathological processes, including cell survival, cell proliferation, and cancer ( Zhu et al, 2016 ; Su et al, 2020 ). It was reported that CIRBP had different effects in various cancers according to the cell context such as acting as a tumor suppressor in rectal carcinoma, endometrial carcinoma, and ovarian tumor and having pro-tumorigenic influences on melanoma, colorectal cancer, prostate cancer, central-nervous-system-related tumor, liver-pancreas carcinomas, skin squamous cell carcinoma, bladder cancer, and pituitary corticotrope adenoma ( Zhu et al, 2016 ; Liao et al, 2017 ; Zhong and Huang, 2017 ; Chen et al, 2018 ; Colasanti et al, 2018 ; Lujan et al, 2018 ; Lin et al, 2019 ). Some studies found down-expressed CIRBP to be always related with poor-survival cell-cycle process and disease stage in BRCA patients ( Joe and Nam, 2016 ; Rodrigues-Peres et al, 2019 ).…”